ACE2 and COVID-19: Our observation of upregulated Rho GTPase signaling in COVID-19 patients is in line with the potential use of Rho kinase inhibitors to treat COVID-19; Rho kinase inhibitors can restore the activity and level of ACE2 which is inhibited by SARS-CoV-2 without increasing the risk of infection (Abedi et al., 2020b).